Abstract
We investigated the effects of a calcium antagonist, efonidipine, which was reported to dilate not only afferent arterioles but also efferent arterioles, on progression of renal failure in salt-loaded partially nephrectomized spontaneously hypertensive rats (SHR). Forty-four SHR's with 5 of 6 nephrectomy were divided into four groups: group I as control (n=20); group 2, efonidipine-treated (n=8); group 3, enalapril-treated (n=8); and group 4, nifedipine-treated (n=8). The rats were given these drugs and a high-salt diet (5% NaCl) for 8 weeks. During the experiment, systolic blood pressure (SBP) and daily urinary, protein excretion were measured every 2 weeks. At the end of the study, serum creatinine was determined, and renal tissues were obtained for light microscopic examination. SBP was markedly reduced by 8-week antihypertensive treatment. (control, 267±7 mmHg; efonidipine, 181±7 mmHg; enalapril, 200±12 mmHg; nifedipine, 184±6 mmHg). Glomerular sclerosis developed markedly in the control group, but was partially prevented in all treated groups. Similarly, urinary protein excretion (UPE) was suppressed by efonidipine (180±16 mg/day) and enalapril (186±16 mg/day vs. 301±28 mg/day for control). In contrast, nifedipine failed to prevent the increase in urinary protein excretion (258±22 mg/day). In conclusion, efonidipine attenuates SBP increase and ameliorates glomerular injury as well as nifedipine and enalapril. Furthermore, beneficial effects of efonidipine, but not nifedipine, on proteinuria suggest that different mechanisms mediate the improvement of proteinuria; one possible mechanism could be efferent arteriolar dilation, not reported in nifedipine.
| Original language | English |
|---|---|
| Pages (from-to) | 295-312 |
| Number of pages | 18 |
| Journal | Clinical and Experimental Hypertension |
| Volume | 20 |
| Issue number | 3 |
| Publication status | Published - 1998 Apr |
Fingerprint
Keywords
- Calcium antagonists
- Efonidipine
- Enalapril
- Glomerular injury
- Hypertension
- Nifedipine
ASJC Scopus subject areas
- Internal Medicine
Cite this
Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. / Fujiwara, Keiji; Kanno, Yoshihiko; Hayashi, Koichi; Takenaka, Tsuneo; Saruta, Takao.
In: Clinical and Experimental Hypertension, Vol. 20, No. 3, 04.1998, p. 295-312.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats
AU - Fujiwara, Keiji
AU - Kanno, Yoshihiko
AU - Hayashi, Koichi
AU - Takenaka, Tsuneo
AU - Saruta, Takao
PY - 1998/4
Y1 - 1998/4
N2 - We investigated the effects of a calcium antagonist, efonidipine, which was reported to dilate not only afferent arterioles but also efferent arterioles, on progression of renal failure in salt-loaded partially nephrectomized spontaneously hypertensive rats (SHR). Forty-four SHR's with 5 of 6 nephrectomy were divided into four groups: group I as control (n=20); group 2, efonidipine-treated (n=8); group 3, enalapril-treated (n=8); and group 4, nifedipine-treated (n=8). The rats were given these drugs and a high-salt diet (5% NaCl) for 8 weeks. During the experiment, systolic blood pressure (SBP) and daily urinary, protein excretion were measured every 2 weeks. At the end of the study, serum creatinine was determined, and renal tissues were obtained for light microscopic examination. SBP was markedly reduced by 8-week antihypertensive treatment. (control, 267±7 mmHg; efonidipine, 181±7 mmHg; enalapril, 200±12 mmHg; nifedipine, 184±6 mmHg). Glomerular sclerosis developed markedly in the control group, but was partially prevented in all treated groups. Similarly, urinary protein excretion (UPE) was suppressed by efonidipine (180±16 mg/day) and enalapril (186±16 mg/day vs. 301±28 mg/day for control). In contrast, nifedipine failed to prevent the increase in urinary protein excretion (258±22 mg/day). In conclusion, efonidipine attenuates SBP increase and ameliorates glomerular injury as well as nifedipine and enalapril. Furthermore, beneficial effects of efonidipine, but not nifedipine, on proteinuria suggest that different mechanisms mediate the improvement of proteinuria; one possible mechanism could be efferent arteriolar dilation, not reported in nifedipine.
AB - We investigated the effects of a calcium antagonist, efonidipine, which was reported to dilate not only afferent arterioles but also efferent arterioles, on progression of renal failure in salt-loaded partially nephrectomized spontaneously hypertensive rats (SHR). Forty-four SHR's with 5 of 6 nephrectomy were divided into four groups: group I as control (n=20); group 2, efonidipine-treated (n=8); group 3, enalapril-treated (n=8); and group 4, nifedipine-treated (n=8). The rats were given these drugs and a high-salt diet (5% NaCl) for 8 weeks. During the experiment, systolic blood pressure (SBP) and daily urinary, protein excretion were measured every 2 weeks. At the end of the study, serum creatinine was determined, and renal tissues were obtained for light microscopic examination. SBP was markedly reduced by 8-week antihypertensive treatment. (control, 267±7 mmHg; efonidipine, 181±7 mmHg; enalapril, 200±12 mmHg; nifedipine, 184±6 mmHg). Glomerular sclerosis developed markedly in the control group, but was partially prevented in all treated groups. Similarly, urinary protein excretion (UPE) was suppressed by efonidipine (180±16 mg/day) and enalapril (186±16 mg/day vs. 301±28 mg/day for control). In contrast, nifedipine failed to prevent the increase in urinary protein excretion (258±22 mg/day). In conclusion, efonidipine attenuates SBP increase and ameliorates glomerular injury as well as nifedipine and enalapril. Furthermore, beneficial effects of efonidipine, but not nifedipine, on proteinuria suggest that different mechanisms mediate the improvement of proteinuria; one possible mechanism could be efferent arteriolar dilation, not reported in nifedipine.
KW - Calcium antagonists
KW - Efonidipine
KW - Enalapril
KW - Glomerular injury
KW - Hypertension
KW - Nifedipine
UR - http://www.scopus.com/inward/record.url?scp=0031922876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031922876&partnerID=8YFLogxK
M3 - Article
VL - 20
SP - 295
EP - 312
JO - Clinical and Experimental Hypertension
JF - Clinical and Experimental Hypertension
SN - 1064-1963
IS - 3
ER -